News

Optical Biometry

Dr Paul-Rolf Preussner discusses how additional optical measurements are required to improve the accuracy limits in IOL calculation

IOL power: Quo vadis?

Increasing levels of expectations of refractive results is challenging IOL power calculations, reveals Dr Oliver Findl

Following a premium IOL implantation it is now possible to maintain the target refractive error of 0.5 D but errors can still arise in the calculation of the desired IOL power. Modernizing formulae may help to reduce prediction error in IOL power calculations.

Results of an in vitro study of the potentially adverse efefcts of five different topical glaucoma medications and preservatives are revealed

A novel nanosecond laser therapy has stopped the progression of age-related macular degeneration (AMD) and resulted in resolution of drusen and improved visual function in patients with early-stage high-risk AMD.

A specific diode laser is the latest technology to perform several different laser procedures in the ophthalmic practice. Its multi-use capabilities for glaucoma and retinal disease make it a strong choice for the office setting.

The identified nocturnal differences in intraocular pressure (IOP) include reductions in aqueous flow, outflow facility and uveoscleral outflow, according to a study published in the Archives of Ophthalmology.

HOYA Surgical Optics do not expect any disruption to their deliveries and business following the recent earthquakes and tsunami in Japan.

Hemianopic and quadrantanopic people have been declared safe to drive because they make more head movements into their blind field to compensate, according to a recent study published in Investigative Ophthalmology and Visual Science.

Fight for Sight, a charity funding the research for the treatment of blindness and eye disease, has contributed grants totalling £697 350 to 7 recipients

A Biologics License Application (BLA) for VEGF Trap-Eye treatment of neovascular age-related AMD has been submitted to the US Food and Drug Administration (FDA) by Regeneron Pharmaceuticals.

Oral resveratrol SRT501 significantly lowers neuronal damage, in a model of multiple scelrosis (MS).